FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

NCT05304962 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: RGT-419B
DRUG: RGT-419B in combination with hormonal therapy

Sponsor

Regor Pharmaceuticals Inc.